The therapeutic effect of P38MAM is based on the combination of a chemotherapeutic and a P38 inhibitor. P38MAM gains strong relevance, for the triple-negative breast cancer subtype,
against which there is no directed therapy. It comes with a selection marker to sort responsive patients.
BiomedTec is the Proof‐of‐Concept funding programme from IRB Barcelona devoted to validate early‐stage in‐house technologies related to biomedical research. The incubation on the BiomedTec platform fosters the transfer of scientific results to the market, thus returning the investment to society by improving the quality of life of patients.